GLP-1 drugs, also known as incretin treatments ... developing next-generation treatments with stronger weight-loss effects. Others, like Hims & Hers (HIMS), betted on more affordable off-brand ...

Zepbound is the most effective FDA-approved GLP-1 drug for weight loss. Between Novo and Lilly, the GLP-1 industry has become an oligopoly with even less threat from compounders like Hims & Hers ...

The move comes after Novo Nordisk A/S’s blockbuster weight-loss and diabetes drugs came off the US drug shortage list Friday. Hims had been ... which came in at $481.1 million, also beat analyst ...

Several weight loss drug ... FDA-approved drugs. Earlier this week, the FDA clarified its policies, giving companies like Hims & Hers until May 22 to stop selling compounded GLP-1 medications ...

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment ...

Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like Ozempic and Mounjaro. That gamble has now collapsed.